- Conditions
- Parkinson Disease
- Interventions
- PF-06412562, Standard of Care Placebo
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Early Course Schizophrenia Spectrum Disorder
- Interventions
- CVL-562 (PF-06412562) 1 mg, CVL-562 (PF-06412562) 4 mg, CVL-562 (PF-06412562) 15 mg, CVL-562 (PF-06412562) 25 mg, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • New York, New York • Stony Brook, New York + 1 more
- Conditions
- Healthy
- Interventions
- 3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562, PF-06412562 TBD mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut